Shots:

• Gilead has exercised its options to 3 programs in Arcus's portfolio, including both anti-TIGIT molecules, domvanalimab & AB308 along with etrumadenant & quemliclustat & will hold exclusive rights outside the US
• Arcus to receive $725M as option fees along with royalties & the transaction is expected to close at the end of 2021. Both companies will co-develop & co-commercialize and share profits in the US related to these programs
• The companies will accelerate the clinical development of the clinical-stage products and facilitate the investigation of treatment combinations across the portfolios. Gilead will be able to add its portfolio products to existing Arcus studies

Ref: GileadImage: Gilead